Designates October of each year as "Opioid Abuse Prevention Month."
Impact
The major impact of AJR35 will be the institutional support for ongoing education around opioid abuse and addiction. By officially recognizing a month dedicated to prevention, it aims to foster community-level discourse and initiatives aimed at combating this public health crisis. The resolution mandates the Governor to issue annual proclamations and calls for organized activities throughout the state, which can lead to enhanced community involvement and awareness that potentially influences public policy and funding for substance abuse programs.
Overall
In summary, AJR35 seeks to put a spotlight on an urgent and prevalent issue in New Jersey - the opioid crisis. By designating October as Opioid Abuse Prevention Month, this resolution aims to educate the public, support those affected, and promote ongoing efforts to mitigate the impact of opioid abuse across the state. Ensuring effective community involvement in such initiatives will be critical to the resolution's success in affecting meaningful change.
Summary
Assembly Joint Resolution 35 (AJR35) aims to designate October of each year as 'Opioid Abuse Prevention Month' in New Jersey. This initiative seeks to increase awareness about the opiate epidemic, which has claimed numerous lives and has extensive negative effects on the community and healthcare systems. The resolution highlights the alarming statistics surrounding opioid abuse, emphasizing the rapid rise in drug overdose deaths since 1990, largely attributed to prescription painkillers. By observing this month, the resolution encourages public officials and citizens to engage in educational activities about the signs and consequences of opioid abuse.
Contention
Though the resolution is likely to receive broad support, there may be points of contention regarding the sufficiency of education alone to address the opioid crisis. Some may argue that educational initiatives without associated policy reforms or resources for treatment services may fall short of making a tangible difference in combating the epidemic. Additionally, the resolution's focus on education may lead to discussions regarding the responsibilities of pharmaceutical companies and healthcare providers in the opioid crisis.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.